The manufacturer of the CBD extract Epidiolex, GW Pharmaceuticals, reported of positive results of the second placebo-controlled Phase 3 clinical trial of this preparation for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare and severe form of childhood-onset epilepsy. The trial randomized 225 patients into three arms, where Epidiolex was added to the current treatment in a dose of 20mg/kg body weight per day (n=76) or in a dose of 10mg/kg/day (n=73). The other patients (n=76) received a placebo.
Patients taking Epidiolex in the higher dose achieved a median reduction in monthly drop seizures of 42 percent compared with a reduction of 17 percent in patients taking placebo, and patients taking Epidiolex in the lower dose achieved a median reduction in monthly drop seizures of 37 percent. “The positive outcome in this second trial of Epidiolex in patients with Lennox-Gastaut syndrome demonstrates the effectiveness of this product in this particularly difficult to treat, childhood-onset epilepsy,” stated Dr Orrin Devinsky of New York University Langone Medical Centers and principal investigator in the trial.
(*) Photo:Wikimedia Commons